Teladoc adds an employer payment option for GLP-1 drugs, building on its existing self-pay program and care services. Clients are not scheduled to start until 2027, and no sales estimate is given, but the expansion supports its business.
This gives employers another way to help workers pay for GLP-1 medicines outside standard pharmacy plans. Teladoc pairs the payment option with care, nutrition, and lifestyle support. The story gives no sales estimate, but contracted clients and a broader service offering support a positive read.
The program includes FDA-approved GLP-1 medicines from Eli Lilly, but the story gives no estimate of added prescriptions or sales. Its planned 2027 client launches do not establish a change in Lilly's business outlook.
The program includes FDA-approved GLP-1 medicines from Novo Nordisk, but the story gives no estimate of added prescriptions or sales. Its planned 2027 client launches do not establish a change in Novo Nordisk's business outlook.
Get alerts for TDOC
Follow Teladoc Health (TDOC) free. When we publish a story about it, you get the plain-English explanation as an alert.